New Haven, CT, October 21, 2014 – Connecticut United for Research Excellence (CURE) is pleased to announce the appointment of Lawrence Weiss to its Board of Directors. Mr. Weiss’ appointment expands the CURE Board to 12 directors.
“Larry’s legal and business expertise in the medical device industry will expand the CURE Board’s network and knowledge base in this important area of growth for the Connecticut bioscience community. We look forward to working with Larry in support of CURE and its mission,” said Dr. Susan Froshauer, president and CEO of CURE.
Mr. Weiss is General Counsel of the Covidien Surgical Solutions Group, a global health care leader providing surgical technologies and products. Prior to this role, Mr. Weiss served as Chief International Counsel supporting the spin-off of Tyco Healthcare into Covidien, a stand-alone publicly traded company. Mr. Weiss joined Tyco Healthcare as Associate General Counsel and Senior Counsel, supporting the company on corporate, transactional, and compliance matters including antitrust law. Prior to joining Tyco Healthcare, Mr. Weiss worked at Goodwin Proctor, concentrating on corporate transactions, securities offerings and compliance.
Mr. Weiss is a graduate of Tulane University and received his J.D. from Boston University School of Law.